Trial Profile
Study to confirm the clinical benefit rate(CBR) in the use of Fulvestrant for estrogen receptor positive, HER2 negative Japanese postmenopausal advanced and recurrence breast cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 May 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 22 May 2021 Status changed from recruiting to discontinued.
- 04 Feb 2014 Actual initiation date changed from 1 Nov 2013 to 20 Jan 2014 as per University Hospital Medical Information Network Japan (UMIN000012153)
- 08 Nov 2013 New trial record